Lipid use and misuse by the heart

Circulation Research

Volumn 118, Issue 11, 2016, Pages 1736-1751

  Schulze, P Christian ^a,b   Drosatos, Konstantinos ^c   Goldberg, Ira J ^d  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ceramide; diabetes mellitus; heart failure; lipids and lipoprotein metabolism; lipotoxicity; obesity; triglyceride

Indexed keywords

CERAMIDE; FATTY ACID; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL STUDY; DIABETES MELLITUS; DRUG TARGETING; EXPERIMENTAL STUDY; FATTY ACID OXIDATION; HEART; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HUMAN; ISCHEMIA; LIPID METABOLISM; LIPID OXIDATION; LIPID STORAGE; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; LIPOTOXICITY; MYOCARDIAL DISEASE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE; HEART DISEASES; METABOLISM; OXIDATIVE STRESS;

ANIMALS; DIABETES COMPLICATIONS; HEART DISEASES; HUMANS; LIPID METABOLISM; MYOCARDIUM; OXIDATIVE STRESS;

EID: 84971219299     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.306842     Document Type: Article

References (241)

1. Neubauer S, The failing heart-An engine out of fuel. N Engl J Med 2007 356 1140 1151. doi: 10.1056/NEJMra063052
2. Galloway JH, Cartwright IJ, Bennett MJ, Abnormal myocardial lipid composition in an infant with type II glutaric aciduria. J Lipid Res 1987 28 279 284
3. Kelly DP, Strauss AW, Inherited cardiomyopathies. N Engl J Med 1994 330 913 919. doi: 10.1056/NEJM199403313301308
4. Taegtmeyer H, Dilsizian V, Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med 2008 5 SUPPL 2 S42 S48. doi: 10.1038/ncpcardio1186
5. Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M, Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 2004 1015 202 213. doi: 10.1196/annals.1302.017
6. Taegtmeyer H, Sen S, Vela D, Return to the fetal gene program: A suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci 2010 1188 191 198. doi: 10.1111/j.1749-6632.2009.05100.x.
7. Taegtmeyer H, Wilson CR, Razeghi P, Sharma S, Metabolic energetics and genetics in the heart. Ann N Y Acad Sci 2005 1047 208 218. doi: 10.1196/annals.1341.019
8. Chokshi A, Drosatos K, Cheema FH, Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 2012 125 2844 2853. doi: 10.1161/CIRCULATIONAHA.111.060889
9. Schulze PC, Myocardial lipid accumulation and lipotoxicity in heart failure. J Lipid Res 2009 50 2137 2138. doi: 10.1194/jlr.R001115
10. Schulze PC, Lipid metabolism and toxicity in the heart. Circulation 2012 15 805 812
11. Tuunanen H, Engblom E, Naum A, Scheinin M, Någren K, Airaksinen J, Nuutila P, Iozzo P, Ukkonen H, Knuuti J, Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006 12 644 652. doi: 10.1016/j.cardfail.2006.06.005
12. Tuunanen H, Ukkonen H, Knuuti J, Myocardial fatty acid metabolism and cardiac performance in heart failure. Curr Cardiol Rep 2008 10 142 148
13. O'Donnell JM, Zampino M, Alpert NM, Fasano MJ, Geenen DL, Lewandowski ED, Accelerated triacylglycerol turnover kinetics in hearts of diabetic rats include evidence for compartmented lipid storage. Am J Physiol Endocrinol Metab 2006 290 E448 E455. doi: 10.1152/ajpendo.00139.2005
14. Carpenter HM, Myocardial fat infiltration. Am Heart J 1962 63 491 496
15. Alpert MA, Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med. Sci 2001 321 225 236
16. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG, Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003 49 417 423. doi: 10.1002/mrm.10372
17. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H, Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004 18 1692 1700. doi: 10.1096/fj.04-2263com
18. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS, Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation 2007 116 1170 1175. doi: 10.1161/CIRCULATIONAHA.106.645614
19. Nyman K, Granér M, Pentikäinen MO, Lundbom J, Hakkarainen A, Sirén R, Nieminen MS, Taskinen MR, Lundbom N, Lauerma K, Cardiac steatosis and left ventricular function in men with metabolic syndrome. J Cardiovasc Magn Reson 2013 15 103. doi: 10.1186/1532-429X-15-103
20. Knuuti J, Tuunanen H, Metabolic imaging in myocardial ischemia and heart failure. Q J Nucl Med Mol Imaging 2010 54 168 176
21. Naum A, Tuunanen H, Engblom E, Oikonen V, Sipilä H, Iozzo P, Nuutila P, Knuuti J, Simultaneous evaluation of myocardial blood flow, cardiac function and lung water content using [15O]H2O and positron emission tomography. Eur J Nucl Med Mol Imaging 2007 34 563 572. doi: 10.1007/s00259-006-0259-3
22. Khan RS, Kato TS, Chokshi A, Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail 2012 5 340 348. doi: 10.1161/CIRCHEARTFAILURE.111.964031
23. Prosdocimo DA, Anand P, Liao X, Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. J Biol Chem 2014 289 5914 5924. doi: 10.1074/jbc.M113.531384
24. Liao X, Zhang R, Lu Y, Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis. J Clin Invest 2015 125 3461 3476. doi: 10.1172/JCI79964
25. Boudina S, Abel ED, Diabetic cardiomyopathy revisited. Circulation 2007 115 3213 3223. doi: 10.1161/CIRCULATIONAHA.106.679597
26. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, Gropler RJ, Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006 47 598 604. doi: 10.1016/j.jacc.2005.09.030
27. O'Donnell JM, Fields AD, Sorokina N, Lewandowski ED, The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Cardiol 2008 44 315 322. doi: 10.1016/j.yjmcc.2007.11.006
28. Borst P, Loos JA, Christ EJ, Slater EC, Uncoupling activity of long-chain fatty acids. Biochim Biophys Acta 1962 62 509 518
29. Borst P, Slater EC, The oxidation of glutamate by rat-heart sarcosomes. 1960. Biochim Biophys Acta 1989 1000 327 328
30. Mjos OD, Kjekshus JK, Lekven J, Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. J Clin Invest 1974 53 1290 1299. doi: 10.1172/JCI107676
31. Young ME, Patil S, Ying J, Depre C, Ahuja HS, Shipley GL, Stepkowski SM, Davies PJ, Taegtmeyer H, Uncoupling protein 3 transcription is regulated by peroxisome proliferator-Activated receptor (alpha) in the adult rodent heart. FASEB J 2001 15 833 845. doi: 10.1096/fj.00-0351com
32. Peterson LR, Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism. Curr Hypertens Rep 2006 8 451 456
33. Schannwell CM, Schneppenheim M, Perings SM, Zimmermann T, Plehn G, Strauer BE, Alterations of left ventricular function in women with insulin-dependent diabetes mellitus during pregnancy. Diabetologia 2003 46 267 275. doi: 10.1007/s00125-002-1029-9
34. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE, Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002 98 33 39. doi: 64682
35. Grundy SM, Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012 59 635 643. doi: 10.1016/j.jacc.2011.08.080
36. Nakanishi T, Kato S, Impact of diabetes mellitus on myocardial lipid deposition: An autopsy study. Pathol Res Pract 2014 210 1018 1025. doi: 10.1016/j.prp.2014.04.008
37. Ho KK, Pinsky JL, Kannel WB, Levy D, The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993 22 6A 13A
38. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS, Obesity and the risk of heart failure. N Engl J Med 2002 347 305 313. doi: 10.1056/NEJMoa020245
39. McKee PA, Castelli WP, McNamara PM, Kannel WB, The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971 285 1441 1446. doi: 10.1056/NEJM197112232852601
40. Patel VB, Mori J, McLean BA, Basu R, Das SK, Ramprasath T, Parajuli N, Penninger JM, Grant MB, Lopaschuk GD, Oudit GY, ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. Diabetes 2016 65 85 95. doi: 10.2337/db15-0399
41. Alavaikko M, Elfving R, Hirvonen J, Järvi J, Triglycerides, cholesterol, and phospholipids in normal heart papillary muscle and in patients suffering from diabetes, cholelithiasis, hypertension, and coronary atheroma. J Clin Pathol 1973 26 285 293
42. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ, Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008 52 1793 1799. doi: 10.1016/j.jacc.2008.07.062
43. van der Meer RW, Doornbos J, Kozerke S, Schär M, Bax JJ, Hammer S, Smit JW, Romijn JA, Diamant M, Rijzewijk LJ, de Roos A, Lamb HJ, Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 2007 245 251 257. doi: 10.1148/radiol.2451061904
44. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ, Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004 109 2191 2196. doi: 10.1161/01.CIR.0000127959.28627.F8
45. Lamant M, Smih F, Harmancey R, Philip-Couderc P, Pathak A, Roncalli J, Galinier M, Collet X, Massabuau P, Senard JM, Rouet P, ApoO, a novel apolipoprotein, is an original glycoprotein up-regulated by diabetes in human heart. J Biol Chem 2006 281 36289 36302. doi: 10.1074/jbc.M510861200
46. Turkieh A, Caubère C, Barutaut M, Desmoulin F, Harmancey R, Galinier M, Berry M, Dambrin C, Polidori C, Casteilla L, Koukoui F, Rouet P, Smih F, Apolipoprotein O is mitochondrial and promotes lipotoxicity in heart. J Clin Invest 2014 124 2277 2286. doi: 10.1172/JCI74668
47. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K, Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003 107 3040 3046. doi: 10.1161/01.CIR.0000072789.89096.10
48. Marfella R, Di Filippo C, Portoghese M, Barbieri M, Ferraraccio F, Siniscalchi M, Cacciapuoti F, Rossi F, D'Amico M, Paolisso G, Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J Lipid Res 2009 50 2314 2323. doi: 10.1194/jlr.P900032-JLR200
49. Brasaemle DL, Perilipin 5: putting the brakes on lipolysis. J Lipid Res 2013 54 876 877. doi: 10.1194/jlr.E036962
50. Kuramoto K, Sakai F, Yoshinori N, Nakamura TY, Wakabayashi S, Kojidani T, Haraguchi T, Hirose F, Osumi T, Deficiency of a lipid droplet protein, perilipin 5, suppresses myocardial lipid accumulation, thereby preventing type 1 diabetes-induced heart malfunction. Mol Cell Biol 2014 34 2721 2731. doi: 10.1128/MCB.00133-14
51. McManaman JL, Bales ES, Orlicky DJ, Jackman M, MacLean PS, Cain S, Crunk AE, Mansur A, Graham CE, Bowman TA, Greenberg AS, Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease. J Lipid Res 2013 54 1346 1359. doi: 10.1194/jlr.M035063
52. Skinner JR, Harris LA, Shew TM, Abumrad NA, Wolins NE, Perilipin 1 moves between the fat droplet and the endoplasmic reticulum. Adipocyte 2013 2 80 86. doi: 10.4161/adip.22864
53. Straub BK, Gyoengyoesi B, Koenig M, Hashani M, Pawella LM, Herpel E, Mueller W, Macher-Goeppinger S, Heid H, Schirmacher P, Adipophilin/perilipin-2 as a lipid droplet-specific marker for metabolically active cells and diseases associated with metabolic dysregulation. Histopathology 2013 62 617 631. doi: 10.1111/his.12038
54. Wang H, Sreenevasan U, Hu H, Saladino A, Polster BM, Lund LM, Gong DW, Stanley WC, Sztalryd C, Perilipin 5, lipid droplet associated protein, provides physical and metabolic linkage to mitochondria. J Lipid Res 2011 52 2159 2168. doi: 10.1194/jlr.M017939
55. Wend K, Wend P, Drew BG, Hevener AL, Miranda-Carboni GA, Krum SA, ERα regulates lipid metabolism in bone through ATGL and perilipin. J Cell Biochem 2013 114 1306 1314. doi: 10.1002/jcb.24470
56. Wang H, Sreenivasan U, Gong DW, O'Connell KA, Dabkowski ER, Hecker PA, Ionica N, Konig M, Mahurkar A, Sun Y, Stanley WC, Sztalryd C, Cardiomyocyte-specific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunction. J Lipid Res 2013 54 953 965. doi: 10.1194/jlr.M032466
57. Pollak NM, Schweiger M, Jaeger D, Cardiac-specific overexpression of perilipin 5 provokes severe cardiac steatosis via the formation of a lipolytic barrier. J Lipid Res 2013 54 1092 1102. doi: 10.1194/jlr.M034710
58. Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL, Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 1990 265 4266 4272
59. Fan B, Gu JQ, Yan R, Zhang H, Feng J, Ikuyama S, High glucose, insulin and free fatty acid concentrations synergistically enhance perilipin 3 expression and lipid accumulation in macrophages. Metabolism 2013 62 1168 1179. doi: 10.1016/j.metabol.2013.02.013
60. Kuramoto K, Okamura T, Yamaguchi T, Perilipin 5, a lipid droplet-binding protein, protects heart from oxidative burden by sequestering fatty acid from excessive oxidation. J Biol Chem 2012 287 23852 23863. doi: 10.1074/jbc.M111.328708
61. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Hoefler G, Zechner R, Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 2006 312 734 737. doi: 10.1126/science.1123965
62. Haemmerle G, Moustafa T, Woelkart G, ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med 2011 17 1076 1085. doi: 10.1038/nm.2439
63. Gross DN, Miyoshi H, Hosaka T, Zhang HH, Pino EC, Souza S, Obin M, Greenberg AS, Pilch PF, Dynamics of lipid droplet-Associated proteins during hormonally stimulated lipolysis in engineered adipocytes: stabilization and lipid droplet binding of adipocyte differentiation-related protein/adipophilin. Mol Endocrinol 2006 20 459 466. doi: 10.1210/me.2005-0323
64. Paul A, Chan L, Bickel PE, The PAT family of lipid droplet proteins in heart and vascular cells. Curr Hypertens Rep 2008 10 461 466
65. Carley AN, Lewandowski ED, Triacylglycerol turnover in the failing heart. Biochim Biophys Acta 2016 S1388 S1981(16)30064-6. doi: 10.1016/j.bbalip.2016.03.012
66. Carley AN, Bi J, Wang X, Banke NH, Dyck JR, O'Donnell JM, Lewandowski ED, Multiphasic triacylglycerol dynamics in the intact heart during acute in vivo overexpression of cd36. J Lipid Res 2013 54 97 106
67. AbouRjaili G, Shtaynberg N, Wetz R, Costantino T, Abela GS, Current concepts in triglyceride metabolism, pathophysiology, and treatment. Metabolism 2010 59 1210 1220. doi: 10.1016/j.metabol.2009.11.014
68. Ballard FB, Danforth WH, Naegle S, Bing RJ, Myocardial metabolism of fatty acids. J Clin Invest 1960 39 717 723. doi: 10.1172/JCI104088
69. Danforth WH, Ballard FB, Kako K, Choudhury JD, Bing RJ, Metabolism of the heart in failure. Circulation 1960 21 112 123
70. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC, Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010 90 207 258. doi: 10.1152/physrev.00015.2009
71. Sambandam N, Lopaschuk GD, Brownsey RW, Allard MF, Energy metabolism in the hypertrophied heart. Heart Fail Rev 2002 7 161 173
72. Bharadwaj KG, Hiyama Y, Hu Y, Huggins LA, Ramakrishnan R, Abumrad NA, Shulman GI, Blaner WS, Goldberg IJ, Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. J Biol Chem 2010 285 37976 37986. doi: 10.1074/jbc.M110.174458
73. Levak-Frank S, Hofmann W, Weinstock PH, Radner H, Sattler W, Breslow JL, Zechner R, Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal plasma triglyceride and high-density lipoprotein-cholesterol levels. Proc Natl Acad Sci U S A 1999 96 3165 3170
74. Augustus A, Yagyu H, Haemmerle G, Zechner R, Cardiac specific knockout of lipoprotein lipase causes hypertriglyeridemia and altered postprandial lipid metabolism. Circulation 2003 108 258 258
75. He L, Kim T, Long Q, Liu J, Wang P, Zhou Y, Ding Y, Prasain J, Wood PA, Yang Q, Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 2012 126 1705 1716. doi: 10.1161/CIRCULATIONAHA.111.075978
76. Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD, Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 2001 50 123 130
77. Kolwicz SC Jr, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R, Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res 2012 111 728 738. doi: 10.1161/CIRCRESAHA.112.268128
78. Essop MF, Camp HS, Choi CS, Sharma S, Fryer RM, Reinhart GA, Guthrie PH, Bentebibel A, Gu Z, Shulman GI, Taegtmeyer H, Wakil SJ, Abu-Elheiga L, Reduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant mice. Am J Physiol Heart Circ Physiol 2008 295 H256 H265. doi: 10.1152/ajpheart.91489.2007
79. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH, Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000 97 1784 1789
80. Wang P, Lloyd SG, Zeng H, Bonen A, Chatham JC, Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 2005 288 H2102 H2110. doi: 10.1152/ajpheart.00935.2004
81. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED, Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005 146 5341 5349. doi: 10.1210/en.2005-0938
82. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, Dyck JR, CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 2007 116 2139 2147. doi: 10.1161/CIRCULATIONAHA.107.712901
83. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE, A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001 107 813 822. doi: 10.1172/JCI10947
84. Chiu HC, Kovacs A, Blanton RM, Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005 96 225 233. doi: 10.1161/01.RES.0000154079.20681.B9
85. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ, Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003 111 419 426. doi: 10.1172/JCI16751
86. Kienesberger PC, Pulinilkunnil T, Sung MM, Nagendran J, Haemmerle G, Kershaw EE, Young ME, Light PE, Oudit GY, Zechner R, Dyck JR, Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol 2012 32 740 750. doi: 10.1128/MCB.06470-11
87. Lahey R, Wang X, Carley AN, Lewandowski ED, Dietary fat SUPPLy to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation 2014 130 1790 1799. doi: 10.1161/CIRCULATIONAHA.114.011687
88. Osuga J, Ishibashi S, Oka T, Yagyu H, Tozawa R, Fujimoto A, Shionoiri F, Yahagi N, Kraemer FB, Tsutsumi O, Yamada N, Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci U S A 2000 97 787 792
89. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP, The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002 109 121 130. doi: 10.1172/JCI14080
90. Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL, Holloszy JO, Semenkovich CF, Kelly DP, A potential link between muscle peroxisome proliferator- activated receptor-Alpha signaling and obesity-related diabetes. Cell Metab 2005 1 133 144. doi: 10.1016/j.cmet.2005.01.006
91. Cheng L, Ding G, Qin Q, Xiao Y, Woods D, Chen YE, Yang Q, Peroxisome proliferator-Activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun 2004 313 277 286
92. Tontonoz P, Hu E, Spiegelman BM, Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-Activated transcription factor. Cell 1994 79 1147 1156
93. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ, Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007 117 2791 2801. doi: 10.1172/JCI30335
94. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ, PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation. J Clin Invest 2010 120 3443 3454. doi: 10.1172/JCI40905
95. Cha BS, Ciaraldi TP, Park KS, Carter L, Mudaliar SR, Henry RR, Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab 2005 289 E151 E159. doi: 10.1152/ajpendo.00141.2004
96. Vega RB, Huss JM, Kelly DP, The coactivator PGC-1 cooperates with peroxisome proliferator-Activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000 20 1868 1876
97. Karbowska J, Kochan Z, Smoleński RT, Peroxisome proliferator-Activated receptor alpha is downregulated in the failing human heart. Cell Mol Biol Lett 2003 8 49 53
98. Masamura K, Tanaka N, Yoshida M, Kato M, Kawai Y, Oida K, Miyamori I, Myocardial metabolic regulation through peroxisome proliferator-Activated receptor alpha after myocardial infarction. Exp Clin Cardiol 2003 8 61 66
99. Narravula S, Colgan SP, Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-Activated receptor alpha expression during hypoxia. J Immunol 2001 166 7543 7548
100. Razeghi P, Young ME, Abbasi S, Taegtmeyer H, Hypoxia in vivo decreases peroxisome proliferator-Activated receptor alpha-regulated gene expression in rat heart. Biochem Biophys Res Commun 2001 287 5 10. doi: 10.1006/bbrc.2001.5541
101. Parmentier JH, Schohn H, Bronner M, Ferrari L, Batt AM, Dauça M, Kremers P, Regulation of CYP4A1 and peroxisome proliferator-Activated receptor alpha expression by interleukin-1beta, interleukin-6, and dexamethasone in cultured fetal rat hepatocytes. Biochem Pharmacol 1997 54 889 898
102. Cabrero A, Alegret M, Sanchez RM, Adzet T, Laguna JC, Carrera MV, Increased reactive oxygen species production down-regulates peroxisome proliferator-Activated alpha pathway in C2C12 skeletal muscle cells. J Biol Chem 2002 277 10100 10107. doi: 10.1074/jbc.M110321200
103. Lee WJ, Kim M, Park HS, Kim HS, Jeon MJ, Oh KS, Koh EH, Won JC, Kim MS, Oh GT, Yoon M, Lee KU, Park JY, AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun 2006 340 291 295. doi: 10.1016/j.bbrc.2005.12.011
104. Meng RS, Pei ZH, Yin R, Zhang CX, Chen BL, Zhang Y, Liu D, Xu AL, Dong YG, Adenosine monophosphate-Activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-Activated receptor-Alpha signaling pathway. Eur J Pharmacol 2009 620 63 70. doi: 10.1016/j.ejphar.2009.08.024
105. Ravnskjaer K, Boergesen M, Dalgaard LT, Mandrup S, Glucose-induced repression of PPARalpha gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation. J Mol Endocrinol 2006 36 289 299. doi: 10.1677/jme.1.01965
106. Chabowski A, Momken I, Coort SL, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Bonen A, Prolonged AMPK activation increases the expression of fatty acid transporters in cardiac myocytes and perfused hearts. Mol Cell Biochem 2006 288 201 212. doi: 10.1007/s11010-006-9140-8
107. Makinde AO, Gamble J, Lopaschuk GD, Upregulation of 5'-AMP-Activated protein kinase is responsible for the increase in myocardial fatty acid oxidation rates following birth in the newborn rabbit. Circ Res 1997 80 482 489
108. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI, AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A 2002 99 15983 15987. doi: 10.1073/pnas.252625599
109. Long YC, Barnes BR, Mahlapuu M, Steiler TL, Martinsson S, Leng Y, Wallberg-Henriksson H, Andersson L, Zierath JR, Role of AMP-Activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle. Diabetologia 2005 48 2354 2364. doi: 10.1007/s00125-005-1962-5
110. Barnes BR, Long YC, Steiler TL, Leng Y, Galuska D, Wojtaszewski JF, Andersson L, Zierath JR, Changes in exercise-induced gene expression in 5'-AMP-Activated protein kinase gamma3-null and gamma3 R225Q transgenic mice. Diabetes 2005 54 3484 3489
111. Garcia-Roves PM, Osler ME, Holmström MH, Zierath JR, Gain-of-function R225Q mutation in AMP-Activated protein kinase gamma3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle. J Biol Chem 2008 283 35724 35734. doi: 10.1074/jbc.M805078200
112. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP, A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003 100 1226 1231. doi: 10.1073/pnas.0336724100
113. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP, CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007 100 1208 1217. doi: 10.1161/01.RES.0000264104.25265.b6
114. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, Kelly DP, Rescue of cardiomyopathy in peroxisome proliferator-Activated receptor-Alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-Activated receptor-Alpha activators. Circulation 2010 121 426 435. doi: 10.1161/CIRCULATIONAHA.109.888735
115. Morrow JP, Katchman A, Son NH, Trent CM, Khan R, Shiomi T, Huang H, Amin V, Lader JM, Vasquez C, Morley GE, D'Armiento J, Homma S, Goldberg IJ, Marx SO, Mice with cardiac overexpression of peroxisome proliferator-Activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias. Circulation 2011 124 2812 2821. doi: 10.1161/CIRCULATIONAHA.111.056309
116. Kantor PF, Dyck JR, Lopaschuk GD, Fatty acid oxidation in the reperfused ischemic heart. Am J Med. Sci 1999 318 3 14
117. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q, Cardiomyocyte-restricted peroxisome proliferator-Activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004 10 1245 1250. doi: 10.1038/nm1116
118. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, Shoghi K, Welch MJ, Kelly DP, Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 2007 117 3930 3939. doi: 10.1172/JCI32578
119. Georgiadi A, Lichtenstein L, Degenhardt T, Boekschoten MV, van Bilsen M, Desvergne B, Müller M, Kersten S, Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-Activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ Res 2010 106 1712 1721. doi: 10.1161/CIRCRESAHA.110.217380
120. Drosatos K, Bharadwaj KG, Lymperopoulos A, Ikeda S, Khan R, Hu Y, Agarwal R, Yu S, Jiang H, Steinberg SF, Blaner WS, Koch WJ, Goldberg IJ, Cardiomyocyte lipids impair β-Adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab 2011 300 E489 E499. doi: 10.1152/ajpendo.00569.2010
121. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, Schaffer JE, Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003 100 3077 3082. doi: 10.1073/pnas.0630588100
122. Okere IC, Chandler MP, McElfresh TA, Rennison JH, Sharov V, Sabbah HN, Tserng KY, Hoit BD, Ernsberger P, Young ME, Stanley WC, Differential effects of saturated and unsaturated fatty acid diets on cardiomyocyte apoptosis, adipose distribution, and serum leptin. Am J Physiol Heart Circ Physiol 2006 291 H38 H44. doi: 10.1152/ajpheart.01295.2005
123. Bosma M, Dapito DH, Drosatos-Tampakaki Z, Huiping-Son N, Huang LS, Kersten S, Drosatos K, Goldberg IJ, Sequestration of fatty acids in triglycerides prevents endoplasmic reticulum stress in an in vitro model of cardiomyocyte lipotoxicity. Biochim Biophys Acta 2014 1841 1648 1655. doi: 10.1016/j.bbalip.2014.09.012
124. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL, Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 1992 89 11059 11063
125. Newton AC, Johnson JE, Protein kinase C: A paradigm for regulation of protein function by two membrane-Targeting modules. Biochim Biophys Acta 1998 1376 155 172
126. Nishizuka Y, Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992 258 607 614
127. Cheng D, Meegalla RL, He B, Cromley DA, Billheimer JT, Young PR, Human acyl-CoA:diacylglycerol acyltransferase is a tetrameric protein. Biochem J 2001 359 707 714
128. Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, Voelker T, Farese RV Jr, Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001 276 38870 38876. doi: 10.1074/jbc.M106219200
129. Liu L, Shi X, Bharadwaj KG, Ikeda S, Yamashita H, Yagyu H, Schaffer JE, Yu YH, Goldberg IJ, DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem 2009 284 36312 36323. doi: 10.1074/jbc.M109.049817
130. Liu L, Yu S, Khan RS, Homma S, Schulze PC, Blaner WS, Yin Y, Goldberg IJ, Diacylglycerol acyl transferase 1 overexpression detoxifies cardiac lipids in PPARγ transgenic mice. J Lipid Res 2012 53 1482 1492. doi: 10.1194/jlr.M024208
131. Kolwicz SC Jr, Liu L, Goldberg IJ, Tian R, Enhancing Cardiac Triacylglycerol Metabolism Improves Recovery From Ischemic Stress. Diabetes 2015 64 2817 2827. doi: 10.2337/db14-1943
132. Buhman KK, Smith SJ, Stone SJ, Repa JJ, Wong JS, Knapp FF Jr, Burri BJ, Hamilton RL, Abumrad NA, Farese RV Jr, DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002 277 25474 25479. doi: 10.1074/jbc.M202013200
133. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese RV Jr, Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 2000 25 87 90. doi: 10.1038/75651
134. Steinberg SF, Structural basis of protein kinase C isoform function. Physiol Rev 2008 88 1341 1378. doi: 10.1152/physrev.00034.2007
135. Nishizuka Y, Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995 9 484 496
136. Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL, Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci U S A 1997 94 9320 9325
137. Jalili T, Manning J, Kim S, Increased translocation of cardiac protein kinase C beta2 accompanies mild cardiac hypertrophy in rats fed saturated fat. J Nutr 2003 133 358 361
138. Wang J, Liu X, Sentex E, Takeda N, Dhalla NS, Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 2003 284 H2277 H2287. doi: 10.1152/ajpheart.00142.2002
139. Belin RJ, Sumandea MP, Allen EJ, Schoenfelt K, Wang H, Solaro RJ, de Tombe PP, Augmented protein kinase C-Alpha-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. Circ Res 2007 101 195 204. doi: 10.1161/CIRCRESAHA.107.148288
140. Narayan P, Valdivia HH, Mentzer RM Jr, Lasley RD, Adenosine A1 receptor stimulation antagonizes the negative inotropic effects of the PKC activator dioctanoylglycerol. J Mol Cell Cardiol 1998 30 913 921
141. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ, Thai K, Krum H, Gilbert RE, Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009 2 129 137. doi: 10.1161/CIRCHEARTFAILURE.108.765750
142. Liu Q, Chen X, Macdonnell SM, Kranias EG, Lorenz JN, Leitges M, Houser SR, Molkentin JD, Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res 2009 105 194 200. doi: 10.1161/CIRCRESAHA.109.195313
143. Braz JC, Gregory K, Pathak A, PKC-Alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004 10 248 254. doi: 10.1038/nm1000
144. Hambleton M, Hahn H, Pleger ST, Kuhn MC, Klevitsky R, Carr AN, Kimball TF, Hewett TE, Dorn GW II, Koch WJ, Molkentin JD, Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 2006 114 574 582. doi: 10.1161/CIRCULATIONAHA.105.592550
145. Boyle AJ, Kelly DJ, Zhang Y, Cox AJ, Gow RM, Way K, Itescu S, Krum H, Gilbert RE, Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol 2005 39 213 221. doi: 10.1016/j.yjmcc.2005.03.008
146. Drosatos K, Bharadwaj KG, Lymperopoulos A, Ikeda S, Khan R, Hu Y, Agarwal R, Yu S, Jiang H, Steinberg SF, Blaner WS, Koch WJ, Goldberg IJ, Cardiomyocyte lipids impair β-Adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab 2011 300 E489 E499. doi: 10.1152/ajpendo.00569.2010
147. Morino K, Petersen KF, Shulman GI, Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006 55 SUPPL 2 S9 S15. doi: 10.2337/diabetes
148. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI, Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-Associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002 277 50230 50236. doi: 10.1074/jbc.M200958200
149. Liu L, Shi X, Choi CS, Shulman GI, Klaus K, Nair KS, Schwartz GJ, Zhang Y, Goldberg IJ, Yu YH, Paradoxical coupling of triglyceride synthesis and fatty acid oxidation in skeletal muscle overexpressing DGAT1. Diabetes 2009 58 2516 2524. doi: 10.2337/db08-1096
150. Liu L, Trent CM, Fang X, Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure. J Biol Chem 2014 289 29881 29891. doi: 10.1074/jbc.M114.601864
151. Weiss B, Stoffel W, Human and murine serine-palmitoyl-CoA transferase-cloning, expression and characterization of the key enzyme in sphingolipid synthesis. Eur J Biochem 1997 249 239 247
152. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH, Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 1998 273 32487 32490
153. Merrill AH Jr, De novo sphingolipid biosynthesis: A necessary, but dangerous, pathway. J Biol Chem 2002 277 25843 25846. doi: 10.1074/jbc.R200009200
154. Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, Kolesnick RN, Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994 180 525 535
155. Kolesnick RN, Krönke M, Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998 60 643 665. doi: 10.1146/annurev.physiol.60.1.643
156. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, Goldberg IJ, Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008 49 2101 2112. doi: 10.1194/jlr.M800147-JLR200
157. Holland WL, Miller RA, Wang ZV, Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011 17 55 63. doi: 10.1038/nm.2277
158. Chavez JA, Holland WL, Bär J, Sandhoff K, Summers SA, Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem 2005 280 20148 20153. doi: 10.1074/jbc.M412769200
159. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE, Summers SA, Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 2011 121 1858 1870. doi: 10.1172/JCI43378
160. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA, Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007 5 167 179. doi: 10.1016/j.cmet.2007.01.002
161. Janero DR, Burghardt B, Lopez R, Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem Pharmacol 1988 37 4197 4203
162. Sentex E, Sergiel JP, Lucien A, Grynberg A, Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 1997 175 153 162
163. Tappia PS, Phospholipid-mediated signaling systems as novel targets for treatment of heart disease. Can J Physiol Pharmacol 2007 85 25 41. doi: 10.1139/y06-098
164. Lim HY, Wang W, Wessells RJ, Ocorr K, Bodmer R, Phospholipid homeostasis regulates lipid metabolism and cardiac function through SREBP signaling in Drosophila. Genes Dev 2011 25 189 200. doi: 10.1101/gad.1992411
165. Rawson RB, The SREBP pathway-insights from Insigs and insects. Nat Rev Mol Cell Biol 2003 4 631 640. doi: 10.1038/nrm1174
166. Fullerton MD, Hakimuddin F, Bonen A, Bakovic M, The development of a metabolic disease phenotype in CTP:phosphoethanolamine cytidylyltransferase-deficient mice. J Biol Chem 2009 284 25704 25713. doi: 10.1074/jbc.M109.023846
167. Basu P, Alibhai FJ, Tsimakouridze EV, Singh RK, Paglialunga S, Holloway GP, Martino TA, Bakovic M, Male-specific cardiac dysfunction in CTP:phosphoethanolamine cytidylyltransferase (Pcyt2)-deficient mice. Mol Cell Biol 2015 35 2641 2657. doi: 10.1128/MCB.00380-15
168. Park JY, Lee SH, Shin MJ, Hwang GS, Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One 2015 10 e0135228. doi: 10.1371/journal.pone.0135228
169. Goldberg IJ, Trent CM, Schulze PC, Lipid metabolism and toxicity in the heart. Cell Metab 2012 15 805 812. doi: 10.1016/j.cmet.2012.04.006
170. Liu L, Yu S, Khan RS, Ables GP, Bharadwaj KG, Hu Y, Huggins LA, Eriksson JW, Buckett LK, Turnbull AV, Ginsberg HN, Blaner WS, Huang LS, Goldberg IJ, DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res 2011 52 732 744. doi: 10.1194/jlr.M011395
171. Konstantinidis K, Whelan RS, Kitsis RN, Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol 2012 32 1552 1562. doi: 10.1161/ATVBAHA.111.224915
172. Hickson-Bick DL, Buja LM, McMillin JB, Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 2000 32 511 519. doi: 10.1006/jmcc.1999.1098
173. Sparagna GC, Hickson-Bick DL, Buja LM, McMillin JB, A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 2000 279 H2124 H2132
174. Listenberger LL, Ory DS, Schaffer JE, Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001 276 14890 14895. doi: 10.1074/jbc.M010286200
175. Hickson-Bick DL, Sparagna GC, Buja LM, McMillin JB, Palmitate-induced apoptosis in neonatal cardiomyocytes is not dependent on the generation of ROS. Am J Physiol Heart Circ Physiol 2002 282 H656 H664. doi: 10.1152/ajpheart.00726.2001
176. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M, Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006 116 1071 1080. doi: 10.1172/JCI23354
177. Park SY, Cho YR, Kim HJ, Higashimori T, Danton C, Lee MK, Dey A, Rothermel B, Kim YB, Kalinowski A, Russell KS, Kim JK, Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 2005 54 3530 3540
178. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG, Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002 51 3020 3024
179. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED, Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004 53 2366 2374
180. Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Patil S, Youker KA, Taegtmeyer H, Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002 51 2587 2595
181. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS, Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006 55 466 473
182. Belke DD, Larsen TS, Gibbs EM, Severson DL, Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000 279 E1104 E1113
183. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, Abel ED, Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002 109 629 639. doi: 10.1172/JCI13946
184. Summers SA, Garza LA, Zhou H, Birnbaum MJ, Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 1998 18 5457 5464
185. Hajduch E, Balendran A, Batty IH, Litherland GJ, Blair AS, Downes CP, Hundal HS, Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 2001 44 173 183. doi: 10.1007/s001250051596
186. Teruel T, Hernandez R, Lorenzo M, Ceramide mediates insulin resistance by tumor necrosis factor-Alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001 50 2563 2571
187. Stratford S, Hoehn KL, Liu F, Summers SA, Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 2004 279 36608 36615. doi: 10.1074/jbc.M406499200
188. Kellerer M, Mushack J, Seffer E, Mischak H, Ullrich A, Häring HU, Protein kinase C isoforms alpha, delta and theta require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the insulin receptor in human kidney embryonic cells (HEK 293 cells). Diabetologia 1998 41 833 838
189. Cortright RN, Azevedo JL Jr, Zhou Q, Sinha M, Pories WJ, Itani SI, Dohm GL, Protein kinase C modulates insulin action in human skeletal muscle. Am J Physiol Endocrinol Metab 2000 278 E553 E562
190. Motley ED, Kabir SM, Eguchi K, Hicks AL, Gardner CD, Reynolds CM, Frank GD, Eguchi S, Protein kinase C inhibits insulin-induced Akt activation in vascular smooth muscle cells. Cell Mol Biol (Noisy-le-grand) 2001 47 1059 1062
191. Farese RV, Sajan MP, Yang H, Li P, Mastorides S, Gower WR Jr, Nimal S, Choi CS, Kim S, Shulman GI, Kahn CR, Braun U, Leitges M, Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 2007 117 2289 2301. doi: 10.1172/JCI31408
192. Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K, Colucci WS, Beta-Adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-Terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 2003 92 136 138
193. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M, Izumo S, Direct activation of mitochondrial apoptosis machinery by c-Jun N-Terminal kinase in adult cardiac myocytes. J Biol Chem 2002 277 10244 10250. doi: 10.1074/jbc.M112355200
194. Miller TA, LeBrasseur NK, Cote GM, Trucillo MP, Pimentel DR, Ido Y, Ruderman NB, Sawyer DB, Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes. Biochem Biophys Res Commun 2005 336 309 315. doi: 10.1016/j.bbrc.2005.08.088
195. Hreniuk D, Garay M, Gaarde W, Monia BP, McKay RA, Cioffi CL, Inhibition of c-Jun N-Terminal kinase 1, but not c-Jun N-Terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol 2001 59 867 874
196. Drosatos K, Drosatos-Tampakaki Z, Khan R, Homma S, Schulze PC, Zannis VI, Goldberg IJ, Inhibition of c-Jun-N-Terminal kinase increases cardiac peroxisome proliferator-Activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. J Biol Chem 2011 286 36331 36339. doi: 10.1074/jbc.M111.272146
197. Borradaile NM, Buhman KK, Listenberger LL, Magee CJ, Morimoto ET, Ory DS, Schaffer JE, A critical role for eukaryotic elongation factor 1A-1 in lipotoxic cell death. Mol Biol Cell 2006 17 770 778. doi: 10.1091/mbc.E05-08-0742
198. Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, Schaffer JE, Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res 2006 47 2726 2737. doi: 10.1194/jlr.M600299-JLR200
199. Turner MD, Fatty acyl CoA-mediated inhibition of endoplasmic reticulum assembly. Biochim Biophys Acta 2004 1693 1 4. doi: 10.1016/j.bbamcr.2004.05.002
200. Song XJ, Yang CY, Liu B, Wei Q, Korkor MT, Liu JY, Yang P, Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci 2011 8 564 572
201. Singer M, Deutschman CS, Seymour CW, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016 315 801 810. doi: 10.1001/jama.2016.0287
202. Court O, Kumar A, Parrillo JE, Kumar A, Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002 6 500 508
203. Zanotti-Cavazzoni SL, Hollenberg SM, Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care 2009 15 392 397. doi: 10.1097/MCC.0b013e3283307a4e.
204. Ren J, Wu S, A burning issue: do sepsis and systemic inflammatory response syndrome (SIRS) directly contribute to cardiac dysfunction? Front Biosci 2006 11 15 22
205. Hunter JD, Doddi M, Sepsis and the heart. Br J Anaesth 2010 104 3 11. doi: 10.1093/bja/aep339
206. Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, Avidan A, Beeri R, Weissman C, Jaffe AS, Sprung CL, Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 2012 33 895 903. doi: 10.1093/eurheartj/ehr351
207. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE, Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996 183 949 958
208. Hoffmann JN, Werdan K, Hartl WH, Jochum M, Faist E, Inthorn D, Hemofiltrate from patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic compounds. Shock 1999 12 174 180
209. Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE, Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989 169 823 832
210. Drosatos K, Khan RS, Trent CM, Jiang H, Son NH, Blaner WS, Homma S, Schulze PC, Goldberg IJ, Peroxisome proliferator-Activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice. Circ Heart Fail 2013 6 550 562. doi: 10.1161/CIRCHEARTFAILURE.112.000177
211. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, Kelly DP, Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-Activated receptor γ coactivator-1 signaling. Circ Heart Fail 2011 4 474 482. doi: 10.1161/CIRCHEARTFAILURE.110.959833
212. Memon RA, Bass NM, Moser AH, Fuller J, Appel R, Grunfeld C, Feingold KR, Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Biochim Biophys Acta 1999 1440 118 126
213. Memon RA, Fuller J, Moser AH, Smith PJ, Feingold KR, Grunfeld C, In vivo regulation of acyl-CoA synthetase mRNA and activity by endotoxin and cytokines. Am J Physiol 1998 275 E64 E72
214. Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C, Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab 2004 286 E201 E207. doi: 10.1152/ajpendo.00205.2003
215. Uji Y, Yamamoto H, Tsuchihashi H, Maeda K, Funahashi T, Shimomura I, Shimizu T, Endo Y, Tani T, Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality. Surgery 2009 145 550 557. doi: 10.1016/j.surg.2009.01.010
216. Reynolds K, Novosad B, Hoffhines A, Gipson J, Johnson J, Peters J, Gonzalez F, Gimble J, Hill M, Pretreatment with troglitazone decreases lethality during endotoxemia in mice. J Endotoxin Res 2002 8 307 314. doi: 10.1179/096805102125000515
217. Haraguchi G, Kosuge H, Maejima Y, Suzuki J, Imai T, Yoshida M, Isobe M, Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. Intensive Care Med 2008 34 1304 1312. doi: 10.1007/s00134-008-1024-9
218. Chima RS, Hake PW, Piraino G, Mangeshkar P, Denenberg A, Zingarelli B, Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. Crit Care Med 2008 36 2849 2857
219. Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH, Wang P, The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-Activated receptor-gamma. Crit Care Med 2006 34 1874 1882. doi: 10.1097/01.CCM.0000221921.71300.BF.
220. Liu D, Zeng BX, Zhang SH, Yao SL, Rosiglitazone, an agonist of peroxisome proliferator-Activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res 2005 54 464 470. doi: 10.1007/s00011-005-1379-0
221. Zingarelli B, Cook JA, Peroxisome proliferator-Activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 2005 23 393 399
222. Yamauchi T, Kamon J, Waki H, The mechanisms by which both heterozygous peroxisome proliferator-Activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001 276 41245 41254. doi: 10.1074/jbc.M103241200
223. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM, Synthetic peroxisome proliferator-Activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002 25 376 380
224. Gustafson B, Jack MM, Cushman SW, Smith U, Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 2003 308 933 939
225. Fang X, Palanivel R, Cresser J, Schram K, Ganguly R, Thong FS, Tuinei J, Xu A, Abel ED, Sweeney G, An APPL1-AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart. Am J Physiol Endocrinol Metab 2010 299 E721 E729. doi: 10.1152/ajpendo.00086.2010
226. Langley RJ, Tsalik EL, van Velkinburgh JC, An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med 2013 5 195ra95. doi: 10.1126/scitranslmed.3005893
227. Hammer S, Jonker JT, Lamb HJ, van der Meer RW, Zondag W, Sepers JM, de Roos A, Smit JW, Romijn JA, Short-Term hyperglycemic dysregulation in patients with type 1 diabetes does not change myocardial triglyceride content or myocardial function. Diabetes Care 2008 31 1613 1614. doi: 10.2337/dc08-0513
228. Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, Pijl H, Meinders EA, Romijn JA, de Roos A, Smit JW, Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008 52 1006 1012. doi: 10.1016/j.jacc.2008.04.068
229. Hammer S, van der Meer RW, Lamb HJ, de Boer HH, Bax JJ, de Roos A, Romijn JA, Smit JW, Short-Term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008 295 E714 E718. doi: 10.1152/ajpendo.90413.2008
230. Hammer S, van der Meer RW, Lamb HJ, Schär M, de Roos A, Smit JW, Romijn JA, Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men. J Clin Endocrinol Metab 2008 93 497 503. doi: 10.1210/jc.2007-2015
231. Lamb HJ, Smit JW, van der Meer RW, Hammer S, Doornbos J, de Roos A, Romijn JA, Metabolic MRI of myocardial and hepatic triglyceride content in response to nutritional interventions. Curr Opin Clin Nutr Metab Care 2008 11 573 579. doi: 10.1097/MCO.0b013e32830a98e3
232. Kankaanpää M, Lehto HR, Pärkkä JP, Komu M, Viljanen A, Ferrannini E, Knuuti J, Nuutila P, Parkkola R, Iozzo P, Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006 91 4689 4695. doi: 10.1210/jc.2006-0584
233. Wolins NE, Quaynor BK, Skinner JR, Tzekov A, Croce MA, Gropler MC, Varma V, Yao-Borengasser A, Rasouli N, Kern PA, Finck BN, Bickel PE, OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes 2006 55 3418 3428. doi: 10.2337/db06-0399
234. Rupp H, Jacob R, Metabolically-modulated growth and phenotype of the rat heart. Eur Heart J 1992 13 SUPPL D 56 61
235. Bristow M, Etomoxir: A new approach to treatment of chronic heart failure. Lancet 2000 356 1621 1622. doi: 10.1016/S0140-6736(00)03149-4
236. Halbirk M, Nørrelund H, Møller N, Schmitz O, Gøtzsche L, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjær H, Bøtker HE, Wiggers H, Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol 2010 299 H1220 H1225. doi: 10.1152/ajpheart.00475.2010
237. Tuunanen H, Engblom E, Naum A, Någren K, Hesse B, Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J, Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006 114 2130 2137. doi: 10.1161/CIRCULATIONAHA.106.645184
238. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M, Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-Term use of a novel treatment. Circulation 2005 112 3280 3288. doi: 10.1161/CIRCULATIONAHA.105.551457
239. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J, Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008 118 1250 1258. doi: 10.1161/CIRCULATIONAHA.108.778019
240. Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M, Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes 2015 64 673 686. doi: 10.2337/db14-0694
241. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720